Prof. Dr. Dario Neri, Philogen’s CEO and CSO, is giving a lecture entitled “Antibody-Cytokine Fusion Proteins for Cancer Therapy: Late-Stage Clinical Results” Dr. Samuele Cazzamalli, Philogen Head of Small Molecule...
Read moreManagement will provide an update on the industrial programs, including on the topline results from the Nidlegy™ Phase III trial presented at ASCO 2024. Please contact us at IR@philogen.com or...
Read moreThe conference provides an opportunity for investors to learn about Philogen’s progress and to meet CEO/CSO Prof. Dario Neri through a series of one-on-one meetings. Prof. Neri will give a...
Read moreProf. Dr. Axel Hauschild, on behalf of Philogen, is giving a presentation about the Phase III PIVOTAL study on May 31st, entitled “Phase 3 study (PIVOTAL) of neoadjuvant intralesional Daromun...
Read moreDr. Ettore Gilardoni (Head of Mass Spectrometry) will attend the 72nd ASMS conference in Anaheim (2-6 June 2024) and present a poster entitled: “Mass Spectrometry evaluation of glycosylation variants and...
Read moreDr. Andrea Galbiati is giving a presentation about Philochem’s FAP ligand platform on June 9th, entitled “Development of Multivalent OncoFAP Derivatives for the Tumor-Targeted Delivery of Theranostic Radionuclides”. Dr. Samuele...
Read more